Infective DisorderPhase 1NCT07239453
Clinical Trial of Comparing DA-2902 and DA-2902-R in Healthy Adult Subjects
A Phase 1 study testing DA-2902 and DA-2902-R in people with Infective Disorder, run by Dong-A ST Co., Ltd. at 1 site in South Korea.
Trial summary
This study is to compare pharmacokinetics and safety profiles of DA-2902 and DA-2902-R in healthy adult subjects Read more about this study
- Who is it for?
- Ages 19 to 44 yearsHealthy volunteers can take part
- Conditions the study is for
- Infective Disorder
- What is being tested?
- DA-2902 and DA-2902-R
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- 1 siteSouth Korea
- Study dates
- 7 Nov 2025to 6 Dec 2025
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 to 44 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Healthy volunteers
- BMI between 18 and 30 kg/m2
- Body weight: Male≥50kg, Female≥45kg
- Subjects who have signed an informed consent themselves after receiving detailed explanation about clinical study
Who cannot join
- Subjects with clinically significant medical history
- Subjects with history of drug abuse or addicted
- Subjects with allergy or drug hypersensitivity
Trial locations and contacts
1 site in 1 country.
South Korea1 site
CHA University Bundang Medical Center
Seongnam-si, Gyeonggi-do, 13520
About this study
Official title: An Open-Label, Randomized, Single Oral Dose, Two-Sequence, Two-Period, CrossovSer Bioequivalence Study of "DA-2902" and "DA-2902-R" in Healthy Adults Under Fed Conditions
This study is to compare pharmacokinetics and safety profiles of DA-2902 and DA-2902-R in healthy adult subjects
- Conditions
- Infective Disorder
- Being tested
- DA-2902, DA-2902-R
- Medical subject headings
- Communicable Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
DA-2902Drug
single dose administration (DA-2902 one tablet once a day)
DA-2902-RDrug
single dose administration (DA-2902-R one tablet once a day)
| Study group | Role | What they receive |
|---|---|---|
| Sequence A | Experimental | Not described Receives: Drug: DA-2902; Drug: DA-2902-R |
| Sequence B | Experimental | Not described Receives: Drug: DA-2902; Drug: DA-2902-R |
What is being measured
The primary outcome is the main question the study is designed to answer.
AUCt
Measured: pre-dose ~ 72 hr of pose-dose
Cmax
Measured: pre-dose ~ 72 hr of post-dose
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Nov 2025
- Study start7 Nov 2025
- Primary completion18 Nov 2025
- Study completion6 Dec 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Infective DisorderStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 40 participants (actual)
Sponsor and investigators
- Lead sponsor
- Dong-A ST Co., Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07239453
- Sponsor's protocol ID
- DA2902_BE_I
- Status last verified
- Jun 2026
- First submitted
- 16 Nov 2025
- Last updated
- 2 Jun 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Open-Label, Randomized, Single Oral Dose, Two-Sequence, Two-Period, CrossovSer Bioequivalence Study of "DA-2902" and "DA-2902-R" in Healthy Adults Under Fed Conditions
- ClinicalTrials.gov ID
- NCT07239453
- Acronym / sponsor ID
- DA2902_BE_I
- Conditions
- Infective Disorder
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 40 participants (actual)
- Lead sponsor
- Dong-A ST Co., Ltd.Industry (pharma, biotech, devices)
- Study start
- 7 Nov 2025 (actual)
- Primary completion
- 18 Nov 2025 (actual)
- Study completion
- 6 Dec 2025 (actual)
- First posted
- 20 Nov 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is to compare pharmacokinetics and safety profiles of DA-2902 and DA-2902-R in healthy adult subjects
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Sequence A | Experimental | Drug: DA-2902, Drug: DA-2902-R |
| Sequence B | Experimental | Drug: DA-2902, Drug: DA-2902-R |
Who may qualify
- Ages
- 19 to 44 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- Healthy volunteers
- BMI between 18 and 30 kg/m2
- Body weight: Male≥50kg, Female≥45kg
- Subjects who have signed an informed consent themselves after receiving detailed explanation about clinical study
Key exclusion criteria (3 listed)
- Subjects with clinically significant medical history
- Subjects with history of drug abuse or addicted
- Subjects with allergy or drug hypersensitivity
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| DA-2902single dose administration (DA-2902 one tablet once a day) | Drug | Sequence A, Sequence B |
| DA-2902-Rsingle dose administration (DA-2902-R one tablet once a day) | Drug | Sequence A, Sequence B |
Primary outcome
AUCt
Time frame: pre-dose ~ 72 hr of pose-dose
Cmax
Time frame: pre-dose ~ 72 hr of post-dose
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Jun 2026.
Related trials for Infective Disorder
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Not yet recruitingPhase 2/3
A Pivotal Safety and Immunogenicity GBS-NN/NN2 Vaccine Maternal Immunisation Trial
Streptococcus Agalactiae Infection, Neonatal Sepsis
Not yet recruiting
HealthMpowerment Korea: Pilot Testing the Cultural Adaptation of a Digital HIV Intervention for Men Who Have Sex With Men in South Korea
HIV Infections, HIV Prevention and Care
Not yet recruiting
Expanded Diagnostic Strategy in Older Adults Hospitalized With Community-Acquired Acute Respiratory Infection
Acute Respiratory Infection
RecruitingPhase 4
A Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients
Infection, Sepsis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing DA-2902 and DA-2902-R in people with Infective Disorder, run by Dong-A ST Co., Ltd. at 1 site in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
AUCt (time frame: pre-dose ~ 72 hr of pose-dose). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jun 2026.